Zuo M Z, Zhao W L, Wei C G, Zhang C Y, Wen R, Gu Y F, Li M J, Zhang Y Y, Wu J F, Li X, Shen J K
Department of Radiology, Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Zhonghua Yi Xue Za Zhi. 2017 Dec 19;97(47):3693-3698. doi: 10.3760/cma.j.issn.0376-2491.2017.47.003.
To investigate the preliminary applicability of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) score in the condition of 3.0T multi-parametric magnetic resonance imaging (Mp-MRI) combined with clinical classic indicators for the diagnosis of prostate cancer (PCa). The clinical and MRI materials of 247 patients of suspicious prostate disease treated in Second Affiliated Hospital of Soochow University from June 2015 to November 2016 were analyzed retrospectively, including 110 cases with PCa and 137 cases without cancer.All cases underwent the high-resolution axial T(2)-weighted imaging (T(2)WI), diffusion weighted imaging (DWI) and dynamic contrast enhancement-magnetic resonance imaging (DCE-MRI) and were confirmed pathologically by puncture biopsies.The Mp-MRI materials of all cases were scored according to PI-RADS v2.The prostate volume and prostate specific antigen (PSA) density (PSAD) value were calculated according to the formulas.The univariate and multivariate analysis were performed for the observed indicators (age, prostate volume, PSA, PSAD and PI-RADS v2 score) to determine the independent predictors for PCa.Then, a Logistic regression model (combined prediction model) was established by the independent predictors for combined diagnosis of PCa.The receiver operating characteristic curve (ROC) curve analysis was performed to get the sensitivity and specificity of each independent predictor and the model to diagnose PCa.The differences of AUC values of each independent predictor and the model were compared with each other to evaluate the diagnostic performance for PCa. The differences in the age, prostate volume, PSA, PSAD and the PI-RADS v2 score between patients with PCa and non-cancer group were all statistically significant (=2.870, =-4.230, -7.787, -9.477, -10.826, all <0.05). The PSAD and PI-RADS v2 score were independent predictors for PCa (=3.331, 10.546, both <0.05). The Logistic regression combined prediction model by PI-RADS v2 score and PSAD to forecast PCa was Logit()=-5.097+ 2.309×PSAD+ 1.214×PI-RADS v2 score.The area under the curve (AUC) of ROC in the combined model (0.911) was higher than that in the PI-RADS v2 score (0.886) and PSAD (0.851) and the differences were all statistically significant (=2.416, 2.716, both <0.05); but the difference in the AUC value between PI-RADS v2 score and PSAD was not statistically significant (=1.191, =0.234). The diagnostic sensitivity of PSAD, PI-RADS v2 score and the model were: 0.891, 0.782 and 0.855, respectively; the specificity were 0.449, 0.912 and 0.847, respectively on their positive thresholds (0.15 μg·L(-1)·ml(-1,) 4 and -0.82). PI-RADS v2 score combined with PSAD in diagnosing PCa is superior to the single application of them and it can lead to high diagnostic sensitivity and specificity for PCa.
探讨前列腺影像报告和数据系统第2版(PI-RADS v2)评分在3.0T多参数磁共振成像(Mp-MRI)联合临床经典指标诊断前列腺癌(PCa)中的初步适用性。回顾性分析2015年6月至2016年11月在苏州大学附属第二医院接受治疗的247例可疑前列腺疾病患者的临床及MRI资料,其中PCa患者110例,非癌患者137例。所有病例均行高分辨率轴位T2加权成像(T2WI)、扩散加权成像(DWI)及动态对比增强磁共振成像(DCE-MRI),并经穿刺活检病理确诊。所有病例的Mp-MRI资料按PI-RADS v2进行评分。根据公式计算前列腺体积及前列腺特异抗原(PSA)密度(PSAD)值。对观察指标(年龄、前列腺体积、PSA、PSAD及PI-RADS v2评分)进行单因素及多因素分析,以确定PCa的独立预测因素。然后,由独立预测因素建立Logistic回归模型(联合预测模型)用于PCa的联合诊断。进行受试者操作特征曲线(ROC)分析,以获得各独立预测因素及模型诊断PCa的敏感性和特异性。比较各独立预测因素及模型的AUC值差异,以评估其对PCa的诊断效能。PCa组与非癌组患者在年龄、前列腺体积、PSA、PSAD及PI-RADS v2评分方面的差异均有统计学意义(分别为2.870、-4.230、-7.787、-9.477、-10.826,均P<0.05)。PSAD及PI-RADS v2评分是PCa的独立预测因素(分别为3.331、10.546,均P<0.05)。由PI-RADS v2评分及PSAD建立的预测PCa的Logistic回归联合预测模型为Logit(P)=-5.097+2.309×PSAD+1.214×PI-RADS v2评分。联合模型的ROC曲线下面积(AUC)(0.911)高于PI-RADS v2评分(0.886)及PSAD(0.851),差异均有统计学意义(分别为2.416、2.716,均P<0.05);但PI-RADS v2评分与PSAD的AUC值差异无统计学意义(分别为1.191、0.234)。PSAD、PI-RADS v2评分及模型的诊断敏感性分别为0.891、0.782及0.855;在各自的阳性阈值(0.15μg·L-1·ml-1、4及-0.82)下,特异性分别为0.449、0.912及0.847。PI-RADS v2评分联合PSAD诊断PCa优于单独应用,可获得较高的诊断敏感性和特异性。